Antithrombotic properties of rafigrelide: a phase 1, open-label, non-randomised, single-sequence, crossover study

Summary

Platelets play a central role in atherothrombotic events. We investigated the effect of a novel platelet-lowering agent, rafigrelide, on thrombus formation and characteristics. In this phase 1, open-label, non-randomised, single-sequence, crossover study, healthy male volunteers received rafigrelide for 14 days (Period 1). Following a ≥6-week washout period, they then received rafigrelide + acetylsalicylic acid (ASA) for 14 days (Period 2). Thrombus formation was assessed ex vivo using the Badimon perfusion chamber, and thrombus characteristics were assessed using thromboelastography. A total of 15 volunteers were enrolled in the study and were assigned to Panel A or Panel B, which had different schedules of assessments. In Panel A, after treatment with rafigrelide alone (Period 1), mean (± standard deviation) platelet count was reduced from 283 (± 17) × 10⁹/l at Day 1, to 125 (± 47) × 10⁹/l at Day 14 (n=6) and thrombus area reduced under high and low shear conditions. Reductions in thrombus area under high shear conditions correlated with reductions in platelet count (r²=0.11, p=0.022; n=12). Rafigrelide treatment prolonged clot formation time and reduced clot strength. The addition of ASA to rafigrelide (Period 2) had no additional effect on platelet count or thrombus area under high or low shear conditions. Similar results were seen in Panel B for all parameters. The most common adverse events (≥3 participants per period) were thrombocytopenia and headache. While confirming the platelet-lowering effects of rafigrelide, this early phase study also indicates that rafigrelide has antithrombotic properties under both high and low shear conditions.

Keywords

Rafigrelide - platelet-lowering - thrombus formation - Badimon perfu-sion chamber - thromboelastography

• References

• 1 Ombrello C, Block RC, Morrell CN. Our expanding view of platelet functions and its clinical implications. J Cardiovasc Transl Res 2010; 03: 538-546.
• 2 Alexandru N, Popov D, Georgescu A. Platelet dysfunction in vascular pathologies and how can it be treated. Thromb Res 2012; 129: 116-126.
• 3 Arnout J, Hoylaerts MF, Lijnen HR. Haemostasis. Handb Exp Pharmacol 2006; 1-41.
• 4 Badimon L, Badimon JJ, Galvez A. et al. Influence of arterial damage and wall shear rate on platelet deposition - exvivo study in a swine model. Arteriosclerosis 1986; 06: 312-320.
• 5 Badimon L, Padro T, Vilahur G. Extracorporeal assays of thrombosis. Methods Mol Biol 2012; 788: 43-57.
• 6 Hartert H. Coagulation studies using thromboelastography: a new investigai-tion procedure [Blutgerinnungsstudien mit der thrombelastographie, einem neuen untersuchungsverfahren]. Klin Wochenschr 1948; 26: 577-583.
• 7 Powner DJ. Thromboelastography during adult donor care. Prog Transplant 2010; 20: 163-167. quiz 168
• 8 Lewis Jr HD, Davis JW, Archibald DG. et al. Protective effects of aspirin against acute myocardial infarction, death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403.
• 9 Theroux P, Ouimet H, McCans J. et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111.
• 10 Anderson JL, Adams CD, Antman EM. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular An-giography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007; 116: e148-304.
• 11 Antman EM, Anbe DT, Armstrong PW. et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110: 588-636.
• 12 Wiviott SD, Braunwald E, McCabe CH. et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371: 1353-1363.
• 13 Wiviott SD, Braunwald E, Angiolillo DJ. et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008; 118: 1626-1636.
• 14 James S, Angiolillo DJ, Cornel JH, Ticagrelor vs. et al. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010; 31: 3006-3016.
• 15 Wallentin L, Becker RC, Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
• 16 Kastrati A, Mehilli J, Neumann FJ. et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopido-grel pretreatment: the ISAR-REACT 2 randomized trial. J Am Med Assoc 2006; 295: 1531-1538.
• 17 Pescatore SL, Lindley C. Anagrelide: a novel agent for the treatment of myelo-proliferative disorders. Expert Opin Pharmacother 2000; 01: 537-546.
• 18 Tefferi A, Silverstein MN, Petitt RM. et al. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: Mechanism of action, efficacy, toxicity, current indications. Semin Thromb Hemost 1997; 23: 379-383.
• 19 EMA. Xagrid (anagrelide): EPAR - Scientific Discussion. 2007
• 20 Gresele P, Momi S, Falcinelli E. Anti-platelet therapy: phosphodiesterase inhibitors. Br J Clin Pharmacol 2011; 72: 634-646.
• 21 World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. http://www.wma.net/e/policy/b3.htm Accessed on 12 August, 2009
• 22 ICH harmonised tripartite guidelines for good clinical practice 1996. ICH harmonised tripartite guidelines for good clinical practice. 1996 http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf Accessed 11 June, 2012
• 23 Badimon L, Turitto V, Rosemark JA. et al. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials - deposition of in-111 labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J Lab Clin Med 1987; 110: 706-718.
• 24 Osende JI, Badimon JJ, Fuster V. et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 2001; 38: 1307-1312.
• 25 Sarich TC, Osende JI, Eriksson UG. et al. Acute antithrombotic effects of xime-lagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis. J Thromb Haemost 2003; 01: 999-1004.
• 26 Lev EI, Osende JI, Richard MF. et al. Administration of abciximab to patients receiving tirofiban or eptifibatide: Effect on platelet function. J Am Coll Cardiol 2001; 37: 847-855.
• 27 Natarajan A, Marshall SM, Worthley SG. et al. The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus. J Thromb Haemost 2008; 06: 2210-2213.
• 28 Viswanathan GN, Natarajan A, Marshall SM. et al. Higher thrombus burden and impaired clot kinetics in patients with type 2 diabetes mellitus following non ST-elevation acute coronary syndrome. Circulation 2010; 122 (Suppl. 21) A17675.
• 29 Viswanathan GN, Zaman AG, Marshall SM. Thrombus burden, clot kinetics and response to anti-platelet therapy in Type 2 diabetes. Diab Med 2011; 28: 1-2.
• 30 Viswanathan GN, Balasubramaniam K, Harper AG. et al. Higher thrombus, altered clot kinetics and fibrin architecture in patients with type 2 diabetes melli-tus after non ST elevation acute coronary syndrome. Eur Heart J 2012; 33: 309
• 31 Viswanathan GN, Marshall SM, Schechter CB. et al. Thrombus antiplatelet therapy in type 2 diabetes mellitusA prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina. Thromb Haemost 2012; 108: 937-945.
• 32 Viswanathan GN, Zaman AG. Cardiovascular disease in patients with type 2 diabetes mellitus: vulnerable plaques and vulnerable blood. Clin Med 2012; 12: s47-50.
• 33 Reikvam H, Steien E, Hauge B. et al. Thrombelastography. Transf Apher Sci 2009; 40: 119-123.
• 34 Kang YG, Martin DJ, Marquez J. et al. Intraoperative changes in blood-coagulation and thrombelastographic monitoring in liver-transplantation. Anesth and Analg 1985; 64: 888-896.
• 35 Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 2004; 25: 5681-5703.
• 36 Blockmans D, Deckmyn H, Vermylen J. Platelet activation. Blood Rev 1995; 09: 143-156.
• 37 Hamad OA, Bäck J, Nilsson PH. et al. Platelets, complement, and contact activation: partners in inflammation and thrombosiscurrent topics in innate immunity II. Lambris JD, Hajishengallis G. 946 vol Springer; New York: 2012: 185-205.
• 38 Zarbock A, Müller H, Kuwano Y. et al. PSGL-1-dependent myeloid leukocyte activation. J Leukoc Biol 2009; 86: 1119-1124.
• 39 Morel O, Morel N, Freyssinet J-M. et al. Platelet microparticles and vascular cells interactions: A checkpoint between the haemostatic and thrombotic responses. Platelets 2008; 19: 9-23.
• 40 Wiviott SD, Trenk D, Frelinger AL. et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116: 2923-2932.
• 41 Jernberg T, Payne CD, Winters KJ. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopido-grel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27: 1166-1173.
• 42 Buller H, Deitchman D, Prins M. et al. Efficacy safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosisThe Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 06: 1313-1318.
• 43 Cannon CP, Husted S, Harrington RA. et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial (vol 50, pg 1844, 2007). J Am Coll Cardiol 2007; 50: 2196-2196.
• 44 Zafar MU, Farkouh ME, Osende J. et al. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients. Thromb and Haem 2007; 97: 487-492.
• 45 Zafar MU, Ibanez B, Choi BG. et al. A new oral antiplatelet agent with potent antithrombotic properties: Comparison of DZ-697b with clopidogrel in a randomised phase I study. Thromb Haemost 2010; 103: 205-212.
• 46 Zafar MU, Vilahur G, Choi BG. et al. A novel anti-ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects. J Thromb Haemost 2007; 05: 1195-1200.